Figure 5.

Effect of ibrutinib and acalabrutinib in association with anti-platelet drugs. (A, B) Platelet-rich plasma from healthy donors with (A) high sensitivity (HS) or (B) low sensitivity (LS) to ibrutinib was pre-treated or not with the indicated doses of acalabrutinib (ACP) or ibrutinib for 1 h at 37°C and anti-platelets drugs (10 μM indomethacin and/or 10 μM ARC69931MX) were added 10 min before stimulation with collagen 3.3 μg/mL. Platelet aggregation was assessed by turbidimetry during 10 min and results, expressed as percentage of maximal aggregation, are the mean ± standard error of mean of three to five independent experiments. *P<0.05, **P<0.01, ***P<0.001 according to one-way and two-way analyses of variance.